Gaucher disease, mucopolysaccharidosis type I (Scheie disease) and Fabry disease. Lysosomal storage diseases treatable by specific therapies and the importance of differential diagnosis against inflammatory rheumatic diseases;Morbus gaucher, mukopolysaccharidose typ I (Scheie) und morbus Fabry. Spezifisch therapierbare lysosomale speicherkrankheiten und wichtige differenzialdiagnosen zu entzündlich-rheumatischen erkrankungen

Monatsschrift fur Kinderheilkunde

Volumn 154, Issue 4, 2006, Pages 347-359

  Michels, H ^a   Mengel, E ^b   Huppertz, H ^c   Schaefer, R ^d  

^a Kinderklinik Garmisch Partenkirchen   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c KLINIKUM BREMEN MITTE   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Differential diagnosis; Fabry disease; Gaucher disease; Mucopolysaccharidosis type I (Scheie disease); Rheumatic diseases

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; ANTIBIOTIC AGENT; COLCHICINE; IMIGLUCERASE; IMMUNOGLOBULIN; LARONIDASE; LEVO IDURONIDASE; MIGLUSTAT; PENICILLIN DERIVATIVE;

ARTHROPATHY; ARTICLE; BACTERIAL ARTHRITIS; BONE NECROSIS; BONE PAIN; CARDIOMYOPATHY; CEREBROVASCULAR DISEASE; COLLAGEN DISEASE; CORONARY ARTERY ANEURYSM; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; ENDOCARDITIS; ENZYME REPLACEMENT; EPIPHYSIOLYSIS; FABRY DISEASE; FAMILIAL MEDITERRANEAN FEVER; FEVER; FRACTURE; GAUCHER DISEASE; HEPATOSPLENOMEGALY; HUMAN; IRIDOCYCLITIS; JOINT CONTRACTURE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; LABORATORY TEST; LYME DISEASE; LYSOSOME STORAGE DISEASE; OSTEOMYELITIS; PANCYTOPENIA; PROGNOSIS; RHEUMATIC DISEASE; RHEUMATIC FEVER; SCHEIE SYNDROME; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMIC DISEASE; VASCULAR DISEASE;

EID: 33745175475     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-006-1324-5     Document Type: Article

References (34)

1. Meikle PJ, Hopwood JJ, Clague AE et al. (1999) Prevalence of lysosomal storage disorders. Jama 281: 249-254
2. Poorthuis BJ, Wevers RA, Kleijer WJ et al. (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105: 151-156
3. Hollak CE, Levi M, Berends F et al. (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96: 470-476
4. Shoenfeld Y, Gallant LA, Shaklai M et al. (1982) Gaucher's disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med 106: 388-391
5. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT et al. (2003) Transglycosidase activity of chitotriosidase: improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278: 40.911-40.916
6. Boot RG, Verhoek M, De Fost M et al. (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103: 33-39
7. Beutler E, Gelbart T (1998) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 24: 2-8
8. Charrow J, Andersson HC, Kaplan P et al. (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835-2843
9. Zimran A, Kay A, Gelbart T et al. (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71: 337-353
10. Rosenthal DI, Barton NW, McKusick KA et al. (1992) Quantitative imaging of Gaucher disease. Radiology 185: 841-845
11. Barton NW, Brady RO, Dambrosia JM et al. (1991) Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464-1470
12. Charrow J, Andersson HC, Kaplan P et al. (2004) Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144: 112-120
13. Niederau C, Rolfs A, vom Dahl S et al. (2001) Diagnose und Therapie des Morbus Gaucher. Aktuelle Empfehlungen der deutschen Therapiezentren im Jahr 2000. Med Klin 96: 32-39
14. Cox T, Lachmann R, Hollak C et al. (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355: 1481-1485
15. Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Valle D et al. (eds) The metabolic and molecular basis of inherited disease. McGraw Hill, New York, pp 3421-3452
16. Cleary MA, Wraith JE (1995) The presenting features of mucopolysaccharidosis type IH (Hurler syndrome). Acta Paediatr 84: 337-339
17. Hein LK, Hopwood JJ, Clements PR et al. (2003) The alpha-L-iduronidase mutations R89Q and R89 W result in an attenuated mucopolysaccharidosis type I clinical presentation. Biochim Biophys Acta 1639: 95-103
18. Dumas HM, Fragala MA, Haley SM et al. (2004) Physical performance testing in mucopolysaccharidosis I: a pilot study. Pediatr Rehabil 7: 125-131
19. Braunlin EA, Stauffer NR, Peters CH et al. (2003) Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 92: 882-886
20. Staba SL, Escolar ML, Poe M et al. (2004) Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350: 1960-1969
21. Wraith JE, Clarke LA, Beck M et al. (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144: 581-588
22. Wraith JE (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6: 489-506
23. Desnick RJ, Ioannou Y, Eng CM (2001) Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W et al. (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, pp 3733-3774
24. Desnick R, Ioannou Y, Eng C (2001) Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Sly WS, Beaudet AL (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 2741-2784
25. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769-775
26. Ries M, Ramaswami U, Parini R et al. (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162: 767-772
27. Branton MH, Schiffmann R, Sabnis SG et al. (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81: 122-138
28. Desnick RJ, Brady R, Barranger J et al. (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138: 338-346
29. Eng CM, Guffon N, Wilcox WR et al. (2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345: 9-16
30. Thurberg BL, Rennke H, Colvin RB et al. (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62: 1933-1946
31. Weidemann F, Breunig F, Beer M et al. (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108: 1299-1301
32. Mathies H, Truckenbrodt H, Sänger L et al. (1988) Diagnostische Kriterien der juvenilen chronischen Arthritis. EULAR, Basel
33. Giannini EH, Brewer EJ (1987) Poor correlation between the erythrocyte sedimentation rate and clinical activity in juvenile rheumatoid arthritis. Clin Rheumatol 6: 197-201
34. Sherry DD (2004) Diagnose und Therapie von Schmerzverstä rkungssyndromen bei Kindern: Erfahrung aus zwei Jahrzehnten. Aktuelle Rheumatol 29: 137-141